Underutilization of Surgery in Periampullary Cancer Treatment
- 202 Downloads
Site-specific outcomes of resection for periampullary cancer have not been analyzed on a large, registry-based scale.
We assessed data on periampullary cancers from the SEER database. Site- and stage-specific outcomes were analyzed. Resection was compared to no resection.
Resection was the main therapy in stages 1 and 2 (resection vs. no resection, 8644 vs. 7208 patients), was less frequent in stage 3 (1248 vs. 2783 patients) and was rarely—but still—used in stage 4 disease (541 vs. 11,212 patients). Pancreatic head (75.7%), 11.4% distal bile duct, 7.7% ampullary, and 5.3% duodenal cancers. Cancer subtype-independent median survival was 22.0 (resection) vs. 7.0 months (no resection) in stages 1 and 2, 21.0 vs. 8.0 months in stage 3, and 10.0 vs. 3.0 months in stage 4. Subtype-dependent median survival (resection vs. no resection) was 18.0 vs. 5.0 months in pancreatic head, 19.0 vs 4.0 months in distal bile duct, 41.0 vs 7.0 months in ampullary, and 38.0 vs 4.0 months in duodenal adenocarcinoma. On multivariable analysis, patient comorbidities, marital and insurance status, and income all influenced the decision to undergo resection.
Surgery is still underutilized in the treatment of periampullary cancers. Patients with cancers originating from the duodenum or the ampulla of Vater benefit most from resectional surgery.
KeywordsPeriampullary cancer Resection SEER database
We would like to thank Claudia Bernardi for the continuous support during the preparation of this study.
Christoph W. Michalski, Bing Liu, and Max Heckler designed the study, performed data acquisition and statistical analysis, and prepared the manuscript.
Susanne Roth, Ulrike Heger, and Huihui Sun contributed to the quality control of the data and to manuscript editing.
Markus W. Büchler and Thilo Hackert contributed to the design of the study and edited the manuscript.
- 7.Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D, Committee EG. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5: v56–68.CrossRefGoogle Scholar
- 8.Pancreatric Section BSoG, Pancreatic Society of Great B, Ireland, Association of Upper Gastrointestinal Surgeons of Great B, Ireland, Royal College of P, Special Interest Group for Gastro-Intestinal R. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54 Suppl 5: v1–16.Google Scholar
- 10.Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Zakelj M, Zadnik V, Becker N, Hackert T, Magi M, Cassetti T, Sassatelli R, Grutzmann R, Merkel S, Goncalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Buchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2017.Google Scholar
- 11.Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.3.2.
- 12.Registries in SEER: https://seer.cancer.gov/registries/terms.html
- 13.Liang W, He J, Shen Y, Shen J, He Q, Zhang J, Jiang G, Wang Q, Liu L, Gao S, Liu D, Wang Z, Zhu Z, Ng CS, Liu CC, Horsleben Petersen R, Rocco G, D'Amico T, Brunelli A, Chen H, Zhi X, Liu B, Yang Y, Chen W, Zhou Q, He J. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol 2017;35(11): 1162–1170.CrossRefGoogle Scholar
- 16.Warschkow R, Guller U, Tarantino I, Cerny T, Schmied BM, Thuerlimann B, Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016;263(6): 1188–1198.Google Scholar
- 17.Bhangu A, Brown G, Nicholls RJ, Wong J, Darzi A, Tekkis P. Survival outcome of local excision versus radical resection of colon or rectal carcinoma: a Surveillance, Epidemiology, and End Results (SEER) population-based study. Ann Surg 2013;258(4): 563–569.Google Scholar
- 18.Fritz AG. International Classification of Diseases for Oncology: ICD-O. Geneva: World Health Organization, 2000.Google Scholar
- 19.Follow-up process in SEER: https://training.seer.cancer.gov/followup/process/
- 26.Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology 2016;68(2): 210–220.CrossRefGoogle Scholar
- 30.La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, Balducci G, Ziparo V, Ramacciato G. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Pancreatology 2014;14(4): 289–294.CrossRefGoogle Scholar